Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Recommendation of “Moderate Buy” by Analysts

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) has been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $53.50.

Several brokerages have weighed in on SLN. HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a research note on Wednesday, June 17th. Cantor Fitzgerald assumed coverage on Silence Therapeutics in a research note on Wednesday, June 24th. They issued an “overweight” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Friday, July 17th. Finally, Morgan Stanley lifted their target price on Silence Therapeutics from $25.00 to $32.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Nantahala Capital Management LLC raised its stake in shares of Silence Therapeutics by 48.0% in the fourth quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company’s stock valued at $9,378,000 after acquiring an additional 500,000 shares during the period. Millennium Management LLC lifted its holdings in shares of Silence Therapeutics by 121.0% in the 4th quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock worth $4,010,000 after acquiring an additional 361,080 shares during the last quarter. 5AM Venture Management LLC purchased a new position in shares of Silence Therapeutics during the 2nd quarter worth about $5,228,676. UBS Group AG boosted its stake in shares of Silence Therapeutics by 34.5% during the 3rd quarter. UBS Group AG now owns 307,363 shares of the company’s stock worth $1,595,000 after purchasing an additional 78,854 shares during the period. Finally, SG Americas Securities LLC grew its holdings in Silence Therapeutics by 11.8% during the 1st quarter. SG Americas Securities LLC now owns 286,698 shares of the company’s stock valued at $1,511,000 after purchasing an additional 30,358 shares during the last quarter. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Price Performance

SLN stock opened at $13.42 on Monday. Silence Therapeutics has a 52 week low of $4.19 and a 52 week high of $17.58. The firm has a market capitalization of $808.02 million, a P/E ratio of -10.48 and a beta of 1.39. The company has a fifty day simple moving average of $11.49 and a two-hundred day simple moving average of $8.11.

Silence Therapeutics (NASDAQ:SLN) last announced its earnings results on Monday, August 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 106.94%. As a group, analysts anticipate that Silence Therapeutics will post -1.03 EPS for the current year.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.